Impax Asset Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Impax Asset Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.85M	Sell	4,134 -488	-11%	-$228K	0.01%	253
2025 Q4	$2.1M	Hold	4,622	–	–	0.01%	232
2025 Q3	$1.81M	Hold	4,622	–	–	0.01%	224
2025 Q2	$2.06M	Sell	4,622 -2,377	-34%	-$1.1M	0.01%	230
2025 Q1	$3.39M	Buy	6,999 +75	+1%	+$35K	0.02%	221
2024 Q4	$2.79M	Sell	6,924 -509	-7%	-$236K	0.01%	238
2024 Q3	$3.46M	Sell	7,433 -45,963	-86%	-$22.1M	0.01%	234
2024 Q2	$25M	Sell	53,396 -14,362	-21%	-$6.23M	0.1%	116
2024 Q1	$28.3M	Sell	67,758 -16,555	-20%	-$7M	0.11%	122
2023 Q4	$34.3M	Sell	84,313 -473,825	-85%	-$175M	0.14%	114
2023 Q3	$194M	Sell	558,138 -25,782	-4%	-$9.02M	0.87%	39
2023 Q2	$205M	Sell	583,920 -178,427	-23%	-$60.1M	0.82%	43
2023 Q1	$240M	Sell	762,347 -1,664	-0.2%	-$499K	1%	35
2022 Q4	$220M	Buy	764,011 +66,278	+9%	+$20.2M	0.99%	37
2022 Q3	$202M	Sell	697,733 -23,201	-3%	-$6.68M	1.04%	33
2022 Q2	$203M	Sell	720,934 -139,738	-16%	-$37.4M	0.99%	35
2022 Q1	$225M	Sell	860,672 -172,183	-17%	-$40.9M	0.93%	39
2021 Q4	$227M	Sell	1,032,855 -41,881	-4%	-$8.14M	0.83%	47
2021 Q3	$195M	Buy	1,074,736 +319,209	+42%	+$62.3M	0.8%	49
2021 Q2	$152M	Buy	755,527 +666,559	+749%	+$139M	0.67%	55
2021 Q1	$19.1M	Buy	88,968 +13,396	+18%	+$2.94M	0.1%	109
2020 Q4	$17.9M	Buy	75,572 +10,381	+16%	+$2.38M	0.11%	100
2020 Q3	$17.7M	Buy	65,191 +18,641	+40%	+$5.14M	0.16%	91
2020 Q2	$13.5M	Sell	46,550 -6,121	-12%	-$1.66M	0.14%	102
2020 Q1	$12.5M	Buy	52,671 +7,880	+18%	+$1.81M	0.17%	101
2019 Q4	$9.81M	Buy	44,791 +468	+1%	+$94.7K	0.11%	117
2019 Q3	$7.51M	Buy	44,323 +39,709	+861%	+$7.02M	0.1%	137
2019 Q2	$846K	Buy	4,614 +444	+11%	+$77.6K	0.01%	204
2019 Q1	$767K	Buy	4,170 +703	+20%	+$130K	0.01%	235
2018 Q4	$575K	Buy	3,467 +66	+2%	+$11.4K	0.01%	222
2018 Q3	$656K	Buy	+3,401	New	+$606K	0.01%	230

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Impax Asset Management Group's VRTX Position: Q1 2026 in Review

Impax Asset Management Group reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q1 2026, selling an estimated $228K and leaving 4,134 shares worth $1.85M. The position accounts for 0.01% of the portfolio, ranked #253.

Impax Asset Management Group first reported a position in VRTX in Q3 2018 and has held it in 31 quarters since. The position peaked at $240M in Q1 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Impax Asset Management Group held 4,134 shares of Vertex Pharmaceuticals worth $1.85M as of Q1 2026.
Impax Asset Management Group sold 488 Vertex Pharmaceuticals shares in Q1 2026, an estimated $228K.
Vertex Pharmaceuticals made up 0.01% of Impax Asset Management Group's portfolio in Q1 2026, its #253 holding.
Impax Asset Management Group first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
Impax Asset Management Group's Vertex Pharmaceuticals position peaked at $240M in Q1 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Impax Asset Management Group's 13F filing for Q1 2026, filed 12 May 2026.